Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 0.75 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29996480 | 1.00 | SYK (1.00) | SYKFLT3AURKB | |
| SCHEMBL27405237 | 1.00 | SYK (1.00) | SYKFLT3AURKB | |
| SCHEMBL27087662 | 1.00 | SYK (1.00) | SYKFLT3AURKB | |
| SCHEMBL524686 | 1.00 | SYK (1.00) | SYKFLT3AURKB | |
| SCHEMBL10196606 | 0.95 | SYK (1.00) | SYKFLT3AURKB | |
| SCHEMBL21025246 | 0.94 | SYK (1.00) | SYKFLT3AURKB | |
| SCHEMBL10196069 | 0.94 | SYK (1.00) | SYKFLT3AURKB | |
| SCHEMBL10196088 | 0.92 | SYK (1.00) | SYKFLT3AURKB | |
| SCHEMBL21025480 | 0.92 | SYK (1.00) | SYKFLT3AURKB | |
| SCHEMBL10196471 | 0.91 | SYK (1.00) | SYKFLT3AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4321160-A1 | COMPOUND FOR PREVENTING OR TREATING DIABETES | Oncocross Co., Ltd. (KR) | 2024-02-14 | — | — | EP | claimed |
| WO-2022215949-A1 | COMPOUND FOR PREVENTING OR TREATING DIABETES | 주식회사 온코크로스 | 2022-10-13 | — | — | WO | claimed |
| WO-2022215950-A1 | COMPOUND FOR PREVENTION OR TREATMENT OF KIDNEY DISEASE | 주식회사 온코크로스 | 2022-10-13 | — | — | WO | claimed |
| US-20240197695-A1 | COMPOUND FOR PREVENTION OR TREATMENT OF KIDNEY DISEASE | ONCOCROSS CO.,LTD (KR) | 2024-06-20 | — | — | US | disclosed |
| EP-4321160-A1 | COMPOUND FOR PREVENTING OR TREATING DIABETES | Oncocross Co., Ltd. (KR) | 2024-02-14 | — | — | EP | disclosed |
| EP-4321161-A1 | COMPOUND FOR PREVENTION OR TREATMENT OF KIDNEY DISEASE | Oncocross Co., Ltd. (KR) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022215949-A1 | COMPOUND FOR PREVENTING OR TREATING DIABETES | 주식회사 온코크로스 | 2022-10-13 | — | — | WO | disclosed |
| WO-2022215950-A1 | COMPOUND FOR PREVENTION OR TREATMENT OF KIDNEY DISEASE | 주식회사 온코크로스 | 2022-10-13 | — | — | WO | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| EP-3119772-B1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-15 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-2528915-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197695-A1 | COMPOUND FOR PREVENTION OR TREATMENT OF KIDNEY DISEASE | GLS, GPR119, ATP6V1B1 | SYK 1614/4885FLT3 4384/4885AURKB 4797/4885 |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | SYK 3856/4885FLT3 2613/4885AURKB 3853/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | SYK 1/4885FLT3 115/4885AURKB 677/4885 |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | SYK, BTK, CD40 | SYK 1/4885FLT3 115/4885AURKB 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.